Subcellular Localization of Mineralocorticoid Receptors in Living Cells: Effects of Receptor Agonists and Antagonists by Fejes-Tóth, Géza et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Peer-reviewed articles by 
Dartmouth faculty Faculty Work 
3-1998 
Subcellular Localization of Mineralocorticoid Receptors in Living 




University of California, San Francisco 
Anikó Náray-Fejes-Tóth 
Dartmouth College 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medical Cell Biology Commons, and the Medical Physiology Commons 
Dartmouth Digital Commons Citation 
Fejes-Tóth, Géza; Pearce, David; and Náray-Fejes-Tóth, Anikó, "Subcellular Localization of 
Mineralocorticoid Receptors in Living Cells: Effects of Receptor Agonists and Antagonists" (1998). Open 
Dartmouth: Peer-reviewed articles by Dartmouth faculty. 1434. 
https://digitalcommons.dartmouth.edu/facoa/1434 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Peer-reviewed articles by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Proc. Natl. Acad. Sci. USA
Vol. 95, pp. 2973–2978, March 1998
Cell Biology
Subcellular localization of mineralocorticoid receptors in living
cells: Effects of receptor agonists and antagonists
GÉZA FEJES-TÓTH*‡, DAVID PEARCE†, AND ANIKÓ NÁRAY-FEJES-TÓTH*
*Department of Physiology, Dartmouth Medical School, Lebanon, NH 03756 and †Department of Medicine, University of California, San Francisco, CA 94110
Communicated by Maria Iandolo New, New York Hospital-Cornell Medical Center, New York, NY, December 19, 1997 (received for review
October 27, 1997)
ABSTRACT Results on the subcellular localization of the
mineralocorticoid receptor (MR) have been controversial. To
determine the subcellular distribution and trafficking of the
MR in living cells after binding of agonists and antagonists,
we expressed a MR-green fluorescent protein (GFP) chimera
in mammalian cells lacking endogenous MR. The GFP-tagged
MR (GFP-MR) remained transcriptionally active, as deter-
mined in cotransfection experiments with the MR-responsive
reporter, TAT3-LUC. The subcellular localization of GFP-MR
was monitored by f luorescence time-lapse microscopy. In the
absence of hormone, MR was present both in the cytoplasm
and nucleus. Aldosterone induced a rapid nuclear accumula-
tion of the MR. Aldosterone-bound GFP-MR was concen-
trated in prominent clusters within the nucleus, whereas
GFP-MR did not form clusters in the absence of hormone.
Similar subnuclear distribution was observed with cortico-
sterone, another MR agonist. In the presence of the MR
antagonists spironolactone or ZK91587 the rate of nuclear
translocation was significantly slower and the final nuclear-
to-cytoplasmic ratio in steady state was significantly lower
than with aldosterone. In addition, MR antagonists did not
induce formation of nuclear GFP-MR clusters. MR antago-
nists also were able to disrupt pre-existing nuclear clusters
formed in the presence of aldosterone. GFP-MR clusters were
retained in nuclear matrix preparations after in vivo
crosslinking. These data strongly suggest that hormone-
activated MRs accumulate in dynamic discrete clusters in the
cell nucleus, and this phenomenon occurs only with transcrip-
tionally active mineralocorticoids.
The mineralocorticoid receptor (MR) is a member of the
steroid-thyroid receptor superfamily. These receptors are li-
gand-dependent transcription factors generally located in the
nucleus even in the absence of the hormone (see ref. 1 for
review). The glucocorticoid receptor (GR), however, is an
exception, because it is mainly cytoplasmic in the absence of
ligand, and nuclear translocation occurs only after hormone
binding (1). The subcellular localization of the MR is still
unclear. Because the MR shows significant sequence homol-
ogy to the GR, one would expect it to also be cytoplasmic in
the absence of hormone. However, previous data on its
localization are controversial. On the one hand, earlier bio-
chemical and immunocytochemical studies found the unligan-
ded MR to be cytoplasmic (2, 3). Similar findings were
reported for the recombinant MR overexpressed in Sf9 insect
cells and mouse macrophages (4). On the other hand, immu-
nohistochemistry of kidney sections from adrenalectomized
animals revealed both nuclear and cytoplasmic staining (2, 5,
6). In addition, a study with enucleated GH3 cells localized
MR entirely to the nucleus (7). All previous studies were done
by using fixed and permeabilized cells and antibodies, and
methodological differences might have contributed to the
controversial results. Furthermore, these studies did not per-
mit examination of the in vivo kinetics of receptor trafficking.
To determine the subcellular distribution of the MR in living
cells, in the present study we used a green fluorescent protein
(GFP)-MR chimera. GFP is an autofluorescent protein that
can be used to study subcellular localization and trafficking of
various proteins, without cell permeabilization, fixation, and
the use of antibodies (8). We expressed a GFP-MR in mam-
malian cells lacking endogenous MR, and monitored its sub-
cellular movements after ligand binding by using fluorescence
time-lapse microscopy.
Another unsettled question in mineralocorticoid physiology
is the mechanisms by which MR antagonists prevent the effects
of aldosterone. In theory, they could block nuclear transloca-
tion of the MR or interfere with a step in signal transduction
after nuclear translocation. Regarding nuclear translocation,
early biochemical studies found that the MR antagonist spi-
ronolactone failed to generate nuclear receptor complexes (9).
Similarly, a recent immunohistochemical study using trans-
fected MR found no nuclear translocation in the presence of
antagonists (3). On the other hand, there is autoradiographic
evidence for nuclear binding of spironolactone (10). These
diverging results can be explained, at least in part, by the
different methods used to determine nuclear binding (i.e.,
isolated nuclei, autoradiography, immunocytochemistry).
Therefore, the second goal of this study was to monitor the
subcellular trafficking of the GFP-MR on treatment with MR
antagonists and examine the fine subnuclear distribution of the
MR by laser-scanning confocal microscopy. We report here
that although cytoplasmic to nuclear translocation of the MR
occurs with both mineralocorticoid agonists and antagonists,
the kinetics of the translocation and the subnuclear distribu-
tion of the MR are strikingly different when liganded to
hormone agonists vs. antagonists.
MATERIALS AND METHODS
Plasmids. The GFP-MR plasmid (pEGFP-rMR), contain-
ing sequences encoding fluorescence-enhanced jellyfish GFP
(8) fused to full-length rat MR (11), was constructed by
inserting the rat MR cDNA fragment downstream of the GFP
sequence into a BglII site within the polylinker of the plasmid
pEGFP-C1 (CLONTECH; see ref. 12). In the resulting fusion
protein the C terminus of EGFP is coupled to the N terminus
of full-length MR through a Ser-Gly-Leu-Arg-Ser sequence.
Cell Culture and Transfection. Chinese hamster ovary
(CHO)-AA8 cells were grown in a-MEM medium containing
10% FetalClone II CHO serum (HyClone), Madin Darby
Canine Kidney (MDCK), and monkey kidney CV1 cells in
DMEMyF12 medium with 10% fetal bovine serum (FBS). To
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Abbreviations: MR, mineralocorticoid receptor; GFP, green fluores-
cent protein; GR, glucocorticoid receptor; CHO, Chinese hamster
ovary; DAPI, 49,6-diamidino-2-phenylindole; MDCK, Madin-Darby
Canine Kidney.
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avoid the influence of possible corticosterone and cortisol
contamination originating from the serum, cells were grown in
media containing FBS that was charcoal-stripped four times.
According to our measurements, this procedure elimi-
nates .99.0% of glucocorticoids present in serum. CHO, CV1,
or MDCK cells were grown in monolayers on small glass
coverslips. Transient transfections were carried out by using
Lipofectamine with 20 ng of the GFP-MR plasmid per cov-
erslip.
Determination of Transcriptional Activity. CV1 cells were
transfected with 50 ng of TAT3-LUC reporter (13) and 500 ng
of pEGFP-rMR or MR expression vector (6RMR), as de-
scribed (14). Twenty nanograms of Rous sarcoma virus-b-
galactosidase plasmid was included as an internal standard and
the BlueScript KS2 vector plasmid was used as carrier to bring
the total amount of DNA to 1 mg. Fresh medium containing
5% stripped serum was added to cells 18 hr before transfection,
and the cells were transfected by using 1 ml Opti-MEM I
reduced serum medium containing Lipofectamine-DNA com-
plex and incubated at 37°C. Five hours later, 1 ml of fresh
DMEM containing 10% stripped fetal bovine serum was
added without removing the transfection mixture, and the cells
were kept at 30°C. Sixteen hours later, medium containing 2
nM aldosterone was added to one of two identical transfec-
tions; 24 hr later, cells were harvested and extracts were
prepared as previously described (13). The extracts were
assayed for luciferase activity at 30°C and were normalized to
protein content and b-galactosidase activity (expression driven
by the Rous sarcoma virus promoter).
Preparation of Nuclear Matrices. CV1 cells grown on
coverslips were treated with 2 nM aldosterone for 30 min at
37°C, then cells were incubated with the in vivo crosslinker,
dithiobis (succinimidyl) propionate (DSP) (1 mM) in Hanks’
solution, for 10 min at 37°C, and then with 1 mM DSP in 100
mM Pipes buffer containing 0.5% Triton X-100, 1 mM EGTA,
4% polyethylene glycol 8000, pH 6.9 for 10 min at 37°C. Cells
were washed, incubated with 0.5% Nonidet P-40, treated with
DNase, and extracted with high salt as described in ref. 15.
Fluorescence Microscopy. Six to 18 hr after transfection with
GFP-MR, the medium was replaced with one containing no
serum, and the coverslips were placed into a heated chamber
under the fluorescence microscope. The cells were kept at
37°C during microscopy. The chamber was perfused with
culture medium (control period) followed by MR agonists or
antagonists as specified below. Fluorescence images were
captured on a PXL cooled charge-coupled device camera
(Photometrics, Tucson, AZ) attached to a Olympus IMT2
microscope equipped with an epifluorescence attachment and
standard f luorescein isothiocyanate, 49-6-diamidino-2-
phenylindole (DAPI), and Texas Red filter sets, using a 603
planapo objective (N.A. 1.4, Nikon). For fluorescence confo-
cal microscopy a Bio-Rad MRC-1024 Laser Scanning Confo-
cal System was used.
RESULTS
The GFP-MR Fusion Protein Is Transcriptionally Active.
We initially wanted to determine whether the GFP-MR fusion
protein behaved similarly to wild-type MR with respect to
transcriptional activity. We therefore transfected CV1b cells
(which lack endogenous MR; ref. 13) with the GFP-MR
plasmid along with the MR-responsive reporter, TAT3-LUC.
The transcriptional activity of GFP-MR at 30°C was consis-
tently comparable to that of the wild-type MR (Fig. 1), whereas
at 37°C, just like with the GR-GFP (16), it was ,10% of that
of the wild-type MR.
Subcellular Distribution of GFP-MR in the Absence and
Presence of Ligand. First we investigated the subcellular
localization of GFP-MR in the absence of hormone, in living
CHO, CV-1, and MDCK cells transiently transfected with
GFP-MR. The majority of transfected cells exhibited both
cytoplasmic and nuclear fluorescence (Fig. 2 A–C). However,
in a small percent of cells GFP-MR seemed to be predomi-
nantly nuclear (Fig. 2D). No GFP-MR was observed in the
nucleoli. This subcellular distribution pattern was similar when
the GFP-MR construct was expressed in epithelial cells
(MDCK; Fig. 2C) or nonepithelial cells (CHO or CV1; Fig. 2
A and B). Furthermore, the distribution pattern (cytoplasmic
plus nuclear vs. predominantly nuclear) was unrelated to the
level of GFP-MR expression (i.e., f luorescence intensity).
In the presence of aldosterone GFP-MR was completely
localized to the nucleus in 100% of the transfected cells. The
time course of nuclear translocation of GFP-MR after aldo-
sterone binding was followed by real-time fluorescence cine-
matography. In cells where GFP-MR was mainly cytoplasmic
in the absence of hormone, nuclear accumulation of GFP-MR
started within 30 sec of addition of 1 nM aldosterone, was
FIG. 2. Subcellular distribution of GFP-MR in the absence of
hormone. CV1 cells (A and D), CHO cells (B), or MDCK cells (C)
were transiently transfected with the GFP-MR plasmid and grown on
coverslips in steroid-free medium at 37°C. Fluorescence images were
captured on a PXL cooled charge-coupled device camera attached to
a Olympus IMT2 microscope equipped with an epifluorescence
attachment and standard fluorescein isothiocyanate filter set, using a
603 planapo objective (N.A. 1.4, Nikon).
FIG. 1. GFP-MR transcriptional activity is comparable to wild-
type MR. CV-1 cells were transiently transfected with the reporter
plasmid TAT3-LUC containing three near-consensus hormone re-
sponse elements upstream of a minimal promoter driving expression
of the luciferase gene. Expression vectors for GFP-MR or wild-type
MR were cotransfected. Cells were incubated for 16 hr with 2 nM
aldosterone at 30°C, as indicated. Shown is the average of four separate
transfections (6SEM) performed on the same day. Comparable
results were obtained in three independent experiments performed on
different days: the ratio of GFP-MR activity to wild-type MR activity
varied by less than 15%.
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half-maximal at 7.5 min, and was complete in about 10 min
(Fig. 3).§
Because corticosterone, an endogenous glucocorticoid, has
the same affinity for the MR as aldosterone, we next tested if
GFP-MR also translocates to the nucleus on binding of
corticosterone, and if so, if it occurs with a kinetics similar to
that of aldosterone. As shown in Fig. 4, incubation of trans-
fected CV1 cells with 2 nM corticosterone also induced
complete nuclear translocation of GFP-MR, and the rate of
translocation was similar to that observed with aldosterone.
Agonist-Liganded GFP-MR Is Localized to Clusters Within
the Nucleus. The subnuclear distribution pattern of aldoste-
rone-activated GFP-MR was examined by confocal laser scan-
ning microscopy. As shown in Fig. 5B, the distribution of
aldosterone-bound GFP-MR within the nucleus is not homog-
enous, in that MRs are concentrated in prominent clusters.
The number of these clusters, as determined by confocal
microscopy (counting the number of local maxima within one
200-nm optical slice and then extrapolating for the total
volume of the nucleus) was found to be between 1,500 and
4,500 per nucleus. Nucleoli were consistently negative. The
punctate nuclear pattern appeared after about 5 min of
aldosterone perfusion. Importantly, GFP-MR never formed
clusters in the absence of hormone. In cells where GFP-MR
was already nuclear without aldosterone, nuclear distribution
was diffuse. In such cells, however, soon after aldosterone
addition the GFP-MR molecules underwent a redistribution,
resulting in the appearance of clusters (Fig. 5). When cells were
incubated at 30°C with aldosterone, formation of nuclear
clusters was very similar to that observed at 37°C (data not
shown).
§A quicktime movie of GFP-MR nuclear localization can be seen at the
Mineralocorticoid Receptor Resource (MRR). The URL is: http://
gladstone.ucsf.edu/givi/pearce/mrr.html.
FIG. 3. Time-dependent nuclear translocation of GFP-MR in the presence of aldosterone. CV1 cells transfected with the GFP-MR plasmid and
grown on coverslips in steroid-free medium, were placed in a chamber maintained at 37°C with steroid-free medium (O min) or 1 nM aldosterone
containing medium, and translocation of GFP-MR was followed in real time, as indicated. Nuclear accumulation of GFP-MR, started within 30
sec was half-maximal at 7.5 min and complete at 10 min.
FIG. 4. Nuclear translocation of GFP-MR occurs with corticosterone as ligand. CV1 cells expressing GFP-MR and grown on coverslips were
perfused with control medium (A) or 1 nM corticosterone for 20 min at 37°C (B).
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Similar subnuclear distribution was observed when GFP-
MR-expressing cells were perfused with corticosterone (Fig.
4B). Again, cluster formation started approximately 5 min
after addition of corticosterone.
Subcellular and Subnuclear Distribution of GFP-MR on
Binding of MR Antagonists. The subcellular localization of
GFP-MR differed markedly when cells were incubated with
MR antagonists, both with respect to the rate and extent of
translocation, and the subnuclear distribution pattern. The
MR antagonists, spironolactone and ZK91587, did not cause
a complete cytoplasmic-to-nuclear translocation of GFP-MR.
Even with high concentrations of spironolactone (up to 1 mM)
and after extended incubation periods (up to 60 min) about
45% of the GFP-MR remained in the cytoplasm (Fig. 6 A vs.
B). The ratio of nuclear to cytoplasmic fluorescence was 28%,
31%, and 45% at 0, 10, and 35 min, respectively, after addition
of 1 mM spironolactone. This process was even slower and less
complete with ZK91587, although this latter compound has
almost as high affinity for the MR as aldosterone (Kd ' 2 nM;
ref. 17). In fact, in most cells there was very little ZK91587-
induced nuclear translocation (Fig. 6 C and D). This obser-
vation is compatible with earlier results showing that the
binding of ZK91587 does not induce activation of the MR (18).
Furthermore, in contrast to aldosterone, spironolactone or
ZK91587 did not induce nuclear clustering of GFP-MR.
Instead, GFP-MR accumulated in a diffuse manner through-
out the nucleoplasm, but again nucleoli were negative. In those
cells where the GFP-MR was nuclear in the absence of ligand,
the nuclear distribution did not change on incubation with
antagonists (Fig. 6 A and B), in strong contrast with the focal
accumulation of GFP-MR observed in such cells in the pres-
ence of aldosterone (Fig. 5B). Thus, nuclear cluster formation
of the MR could be observed only with transcriptionally active
hormones and not with hormone antagonists.
Even more important, MR antagonists were able to disrupt
clusters that formed in the presence of aldosterone. In these
experiments live cells first were treated with 1 nM aldosterone,
and then perfused with 1 mM spironolactone or ZK91587 in
the continued presence of 1 nM aldosterone. As shown in Fig.
6F, the prominent focal accumulation of the GFP-MR ob-
served with aldosterone (Fig. 6E) completely disappeared
within 30 min after the addition of the MR antagonist.
Nuclear GFP-MR Clusters Are Bound to the Nuclear Ma-
trix. Previous observations indicate that steroid receptors bind
to the nuclear matrix when liganded with their respective
hormones (15, 19, 20). Therefore we tested if GFP-MR clusters
are present in nuclear matrix preparations from cells tran-
siently transfected with GFP-MR and incubated with aldoste-
rone. Because the interaction between GR and nuclear matrix
seems relatively weak (15, 19) and can be detected only after
crosslinking, we treated aldosterone-induced CV1 cells with
the crosslinker dithiobis (succinimidyl) propionate before per-
mealizing the cell membrane. Fig. 7 shows that the GFP-MR
clusters were retained in these nuclear matrices. Although this
observation indicates that MRs, like other steroid receptors,
bind to the nuclear matrix in vivo, this interaction is probably
weak, because it required crosslinking to be detected.
Costaining with DNA Dyes. To address the question of
whether the intranuclear distribution pattern of the GFP-MR
correlates with the density of the chromatin, we costained
aldosterone-treated cells with the DNA dyes DAPI or pro-
pidium iodide. As shown in Fig. 8, there was a negative
correlation between the spatial distribution of GFP-MR and
DAPI. Those regions that showed a strong DAPI staining,
probably corresponding to the transcriptionally inactive het-
erochromatin, had few GFP-MR clusters. Similar negative
correlation was observed when using propidium iodide instead
of DAPI (data not shown). These observations suggest that the
GFP-MR clusters preferentially accumulate on euchromatin
and might be associated with the transcriptionally active
regions of the chromatin.
DISCUSSION
In this study we used a GFP-MR fusion protein to examine the
subcellular localization of MR, both in the absence of hormone
as well as after treatment with agonists or antagonists. The use
of GFP-tagged MR makes it possible to monitor intracellular
trafficking in living cells, without the necessity of cell perme-
abilization and use of antibodies. Although a similar approach
recently was applied to study the subcellular distribution of the
GR (16, 21), subcellular trafficking of MR in living cells has
not been examined by this approach.¶
Previous studies indicated that many proteins expressed as
GFP fusions retain the same subcellular localization and biolog-
ical activity as their native counterparts (8, 22, 23). Nevertheless,
we thought it was important to establish that the GFP-MR fusion
protein remains functional. Our experiments with transfected
cells demonstrate that the GFP-MR fusion protein is able to
specifically bind aldosterone, and on TAT3-LUC reporter gene it
is as active as the wild-type MR, indicating that the presence of
the GFP sequence at the N terminus of MR did not alter its
biological activity significantly. This conclusion also is supported
¶While this study was in progress, nuclear localization of GFP-MR was
described in transfected A6 cells, however, subnuclear distribution
was not investigated (12).
FIG. 5. GFP-MR forms nuclear clusters in the presence of aldosterone. Confocal images of a cell before (A) and 15 min after (B) perfusion
with 1 nM aldosterone at 37°C. Formation of nuclear clusters started at about 5 min after aldosterone. Note that no nuclear clusters are present
in the absence of aldosterone even when the MR is mainly nuclear before hormone addition.
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by the observation that the GFP-MR protein exhibited concen-
tration-dependent nuclear translocation in the presence of the
physiological hormone, aldosterone, and practically all GFP-MR
molecules were able to translocate.
Studies on the subcellular localization of the MR in the
absence of steroids have been controversial. There are data
suggesting either exclusively cytoplasmic (3, 4) or nuclear (7)
localization. Studying living cells, we found that in the absence
of ligand GFP-MR was localized to both the cytoplasm and the
nucleus in most cells. This observation would put the MR in a
third category within the steroidythyroid receptor superfamily,
in which the unliganded receptor is not exclusively cytoplasmic
like the GR (21) or nuclear as other members of this family (1),
but rather it localizes to both compartments. A constant
shuttling of unliganded receptors between the cytoplasm and
nucleus has been suggested for other steroid receptors (20, 24),
and such a mechanism is likely to contribute to the observed
localization of the unliganded GFP-MR in this study. How-
ever, we also have observed a few cells where the GFP-MR was
nuclear even in the absence of hormone. Because the fluo-
rescence intensity was similar in cells in which the unliganded
GFP-MR was predominantly cytoplasmic vs. nuclear, different
levels of expression are unlikely to explain this heterogeneity.
One possible explanation is that the subcellular distribution of the
FIG. 8. Comparison of the nuclear distribution of the DNA dye
DAPI and GFP-MR. CV1 cells expressing GFP-MR were incubated
with 1 nM aldosterone at 37°C for 30 min. Then the cells were fixed
with 2% formaldehyde, permeabilized, and incubated with 2 mgyml
DAPI for 15 min at room temperature. (A) Intranuclear distribution
of GFP-MR. (B) Intranuclear distribution of DAPI. Arrows point to
the most dense DNA regions that are negative for GFP-MR.
FIG. 6. Subcellular localization of the GFP-MR in the presence of
MR antagonists. Confocal images of two cells before (A) and after (B)
incubation with 1 mM spironolactone for 45 min at 37°C. C and D are
fluorescence microscopic images of a cell before (C) and after (D)
incubation with 2 nM ZK91587 for 35 min. In all three cells nuclear
translocation of GFP-MR was significantly less than that with aldo-
sterone. (E) Cells were perfused with 1 nM aldosterone for 30 min;
note prominent nuclear clusters. After 30 min, the perfusion medium
was changed to 1 nM aldosterone plus 100 nM spironolactone, and the
image on F was captured 30 min later. Note that spironolactone
treatment disrupted the nuclear clusters.
FIG. 7. Nuclear clusters are associated with the nuclear matrix.
Confocal image of a CV1 cell incubated with 1 nM aldosterone for 30
min at 37°C, then treated with the in vivo crosslinker, dithiobis
(succinimidyl) propionate (1 mM) for 10 min at 37°C, and then nuclear
matrix extracted as described in Materials and Methods.
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MR changes during the cell cycle, and because our cells were not
synchronized, this could have resulted in the observed heteroge-
neity. Alternatively, cell-to-cell variation in the expression levels
of other proteins necessary for MR nuclear localization might be
responsible for the heterogenous distribution. Although we used
serum that was charcoal-stripped four times, and therefore .99%
of endogenous steroids were removed, the possibility that non-
steroidal activation of the MR occurred because of some com-
ponents of the medium cannot be excluded.
Perhaps the most important finding of the present study is that
the subnuclear distribution of MRs is heterogenous in the pres-
ence of agonists. Within the nucleus the receptors accumulate in
clusters, and such clusters form only with hormones that can
activate transcription. We found that both aldosterone and cor-
ticosterone, which are MR agonists, induced nuclear clusters,
whereas the MR antagonists spironolactone and ZK91587 did
not. The subnuclear distribution pattern of the agonist-liganded
GFP-MR is remarkably similar to the pattern of the GR in the
presence of dexamethasone observed either by immunohisto-
chemistry on fixed cells (15, 25) or using a GFP-GR fusion protein
in live cells (21). Furthermore, Htun et al. (21) found no nuclear
clusters in the presence of the GR-antagonist RU486. van
Steensel et al. (26) also observed nuclear clusters of the MR in
fixed hippocampal tissue by using immunohistochemistry, but
distribution of the MR was not affected by adrenalectomy or
hormone replacement. We suspect that the lack of effect of
hormonal conditions on MR distribution in that study (26) might
have been caused by the different specificity of the antibody for
activated vs. nonactivated receptor.
The exact nature and the function of the nuclear clusters is
presently unknown. Htun and coworkers (21) suggested that
with the GR such clusters correspond to activated target genes.
However, optically detectable cluster formation requires prob-
ably many more MR molecules than the number of MRs
expected to be associated with the promoter region of aldo-
sterone-induced genes. Furthermore, it seems unlikely that
aldosterone would increase the transcription of 1,500–4,500
genes (the number of GFP-MR clusters). Therefore, we feel
that these clusters cannot represent only target genes. In
agreement with this idea, van Steensel et al. (15) reported that
in the hippocampus there was no correlation between the
distribution pattern of GR clusters and the distribution of
newly synthesized pre-mRNA, again arguing that the GR
clusters are not directly associated with transcriptional units.
Why then do we see a correlation between transcriptional
activity and the ability to induce cluster formation of a given
steroid? We propose that the observed focal distribution of the
aldosterone-liganded MR represents a necessary step leading
to transcriptional activation. For example, nuclear clusters
(which, as our data show, are still present in nuclear matrix
preparations), may bind to chromatin regions that act as
‘‘ushers’’ to direct the activated receptors to the appropriate
genes. The clustered binding of the MR to such nuclear
acceptor sites might be important in scanning for aldosterone
target genes. Recently Tang and DeFranco (20) proposed a
dynamic model for the GR, speculating that a rapid associa-
tionydissociation of the GR with the nuclear matrix would
facilitate an effective scanning for steroid target genes.
Our data also revealed that MR antagonists can interfere with
aldosterone action by at least two mechanisms: the nuclear
translocation rate of antagonist-liganded GFP-MR is significantly
slower than that observed with aldosterone, and they are not able
to induce nuclear cluster formation of the MR. Our results also
indicate that nuclear cluster formation is rapidly reversible. When
spironolactone or ZK91587 was added after the typical focal
accumulation of MR-aldosterone complexes, the clusters disap-
peared within 30 min, and nuclear distribution of GFP-MR
became homogenous. These data suggest that nuclear cluster
formation is a critical step leading to transcriptional activity. This
conclusion also is supported by our observation that the GFP-MR
clusters preferentially accumulate over regions that show less
intense staining with DNA dyes, probably corresponding to the
transcriptionally more active euchromatin. Previous electron
microscopic studies found that the progesterone receptor was
associated with transcriptionally inactive condensed chromatin in
the absence of progesterone, whereas it was distributed over less
condensed chromatin after hormone addition (1).
In summary, our data strongly suggest that hormone-
activated MRs accumulate in discrete clusters in the cell
nucleus, and this phenomenon occurs only with transcription-
ally active mineralocorticoids. The nature of nuclear clusters,
their acceptor sites, and role in the mechanism of aldosterone
action remain to be determined.
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2978 Cell Biology: Fejes-Tóth et al. Proc. Natl. Acad. Sci. USA 95 (1998)
